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RESUMO 
 O cancro é uma das principais causas de morte em todo o mundo. Estima-se 
que em 2018 existam mais de 18.1 milhões de casos de cancro e 0.5 milhões de 
novos casos em todo o mundo. As metástases cerebrais são o tumor intracraniano 
com maior incidência na idade adulta, ocorrendo mesmo com mais frequência que 
os tumores primários do cérebro. Estima-se que cerca de 20% dos doentes por 
cancro desenvolverão metástases cerebrais, com significativo aumento de 
morbilidade e mortalidade associada a cancro. A principal causa de morte por 
cancro está relacionada com a recaída à distância e, embora o sistema nervoso 
central não seja o local primário de recaída mais frequente, no caso do tumor da 
mama – HER2-amplificado e triplo negativo – existe tropismo para o cérebro, sendo 
frequente o sistema nervoso central o local primário de recaída. Historicamente, o 
prognóstico da doença metastática cerebral é considerado mau e as abordagens 
clássicas de radioterapia, nomeadamente radiocirurgia e radioterapia à totalidade do 
cérebro (Whole-Brain Radiotherapy, WBRT), são tratamento paliativo. Contudo, as 
alternativas terapêuticas que têm surgido nas últimas décadas têm vindo a alterar 
este paradigma. Actualmente, os pacientes vivem mais tempo após o diagnóstico e 
tratamento de metástases cerebrais, o que levanta novas preocupações, 
nomeadamente quanto à toxicidade neurocognitiva associada à terapêutica 
mencionada, e constitui um desafio na prática clínica. Mais ainda, a barreira 
hematoencefálica impede a livre passagem de diversas moléculas e de agentes 
quimioterápicos. No entanto, sofre disrupção ao ser lesada aquando do 
desenvolvimento de metástases cerebrais, o que torna muito relevante a 
investigação de terapêuticas eficazes que a consigam penetrar. 
 Em cancro do pulmão, carcinoma de células renais, melanoma e cancro da 
mama, a incidência de metástases cerebrais revela-se elevada, correspondendo a 
cerca de 16-20%, 6-10%, 6-8% e 5-6%, respectivamente. A prevalência é maior nos 
cancros do pulmão e da mama, mas o maior risco de desenvolvimento de lesões 
secundárias no sistema nervoso central é registado em melanoma. 
 O cancro da mama é tradicionalmente considerado não-imunogénico, no 
entanto, diversos estudos têm vindo a sugerir que o sistema imunitário, incluindo os 
linfócitos que infiltram o tumor (tumour-infiltrating lymphocytes, TILs), tem um papel 
na interacção hospedeiro-tumor. Os TILs, leucócitos que migram para o tumor 
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através da corrente sanguínea, são genericamente considerados indicadores de 
bom prognóstico e preditivos de resposta, nomeadamente em pacientes com cancro 
da mama tratados em neoadjuvância. Existem diferentes subpopulações de TILs 
com funções distintas no microambiente tumoral, incluindo os TILs CD4+ e CD8+, 
biomarcadores de bom prognóstico, particularmente em carcinoma ductal invasivo 
da mama. 
Deste modo, o nosso principal objectivo foi aferir o valor prognóstico de TILs e 
das subpopulações TILs CD4+ e CD8+ no estroma tumoral de metástases cerebrais 
de cancro da mama, no contexto clínico. Os resultados obtidos em cancro da mama 
foram comparados com os resultados obtidos num grupo de doentes com cancros 
do pulmão, do rim, do cólon e melanoma, tumores considerados imunogénicos. 
Como objectivos secundários, propusemo-nos avaliar a presença de astrócitos 
reactivos, células caracterizadas por fenótipo hipertrófico e aumento de densidade e 
rearranjo de GFAP (proteína específica dos filamentos intermédios do citoesqueleto 
de elementos gliais) e que têm sido associadas a metastização cerebral, bem como 
verificar uma possível associação com sobrevida global; e avaliar a expressão de 
PD-L1, uma proteína envolvida na resposta imunitária, em metástases cerebrais. 
Finalmente pretendíamos verificar se o subtipo molecular se alterava entre tumor 
primário da mama e metástase, já que muitas vezes se observa a perda ou ganho 
de expressão de receptores hormonais ou mesmo HER2 no tecido metastático, com 
consequências clínicas importantes sobretudo ao nível da terapêutica. 
A coorte utilizada para este estudo incluía 56 doentes – 34 (60.7%) do sexo 
feminino e 22 (39.3%) do sexo masculino – diagnosticados com metástases 
cerebrais entre 2009 e 2013 e seguidos no Serviço de Oncologia Médica do HSM – 
CHULN. As metástases cerebrais provinham de cancro da mama (n=25, 44.7%), 
cancro do pulmão (n=15, 26.8%), cancro colo-rectal (n=6, 10.7%), cancro do rim 
(n=6, 10.7%) e melanoma (n=4, 7.1%). Todos os doentes foram submetidos a 
radioterapia holocraniana após ressecção cirúrgica. A idade mediana à data do 
diagnóstico era de 58.50 anos e variava entre 28 e 90 anos. Por forma a estudar 
esta coorte, procedemos à análise da coloração hematoxilina e eosina e 
imunohistoquímica dos marcadores acima mencionados na sub-coorte de doentes 
de cancro da mama e, no caso de TILs, CD4 e CD8, comparámos com os resultados 
dos doentes com metástases cerebrais de outras origens. 
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 A análise de sobrevivência mostrou que existe uma associação entre níveis 
elevados de TILs CD8+ no estroma do tumor e uma maior sobrevida no grupo de 
doentes que inclui todos os tipos de tumor primário (Log-rank (Mantel Cox) test: HR 
2.127, 95% CI 1.002-4.518; p=0.0495). O mesmo se observou no grupo que exclui 
os casos com origem em cancro da mama (Log-rank (Mantel Cox) test: HR 0.4290, 
95% CI 0.1370-0.8486; p=0.0296). Observou-se ainda uma tendência para uma 
maior sobrevida, quando os níveis de TILs são elevados. No entanto, em nenhum 
dos grupos – metástases com origem em cancro da mama, incluindo todos os tipos 
de tumor primário ou excluindo cancro da mama – se obteve significância estatística.  
Neste estudo, as amostras com TILs CD4+ ou expressão de PD-L1 foram 
raras. No entanto, num estudo in vitro num painel de linhas celulares tumorais, 
observou-se uma sobre-expressão de PD-L1 (PD-L1) nas linhas com tropismo para 
o cérebro e na linha com tropismo para o osso, quando comparadas com as 
restantes e com células epiteliais mamárias normais. A ligação de PD-L1 ao receptor 
PD-1 liberta um sinal inibitório que reduz a proliferação de células T com 
especificidade para antigénio e, simultaneamente, diminui a apoptose em células T 
regulatórias. No contexto tumoral, é um marcador preditivo de resposta à 
imunoterapia, permitindo identificar os subgrupos de doentes que beneficiarão mais 
da terapêutica com agentes anti-PD-1 ou anti-PD-L1, já que a sua sobre-expressão 
no tumor foi associada a maior agressividade do mesmo, nomeadamente em 
carcinoma de células renais. Finalmente, verificou-se uma alteração de subtipo 
molecular em 52.6% dos casos, incluindo perda ou ganho de receptores hormonais, 
e perda de expressão de HER2 num caso. No contexto dos objectivos secundários 
deste estudo, não foi possível verificar a associação com a densidade linfocitária 
devido ao tamanho reduzido da amostra. 
 Em suma, os resultados obtidos neste projecto mostram uma correlação entre 
elevada densidade de TILs CD8+ e maior sobrevida global, quando analisando todos 
os tipos de tumor primário em conjunto ou excepto cancro da mama e uma 
tendência para maior sobrevida global, nos casos de cancro da mama. Assim, a 
população linfocitária que infiltra o tumor tem relevância no contexto clínico e o 
estudo das suas várias subpopulações será sempre mais útil e informativo do que o 
da população total apenas, uma vez que o valor prognóstico varia entre 
subpopulações (e também é diferente comparando subpopulações e TILs totais). Os 
resultados apontam também para a relevância de estudar o subtipo molecular da 
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metástase cerebral, visto que pode ter impacto na progressão da doença, já que 
algumas linhas terapêuticas não eficazes aquando do diagnóstico do tumor primário 
podem revelar-se eficazes em contexto metastático, como a alteração do status do 
receptor de estrogénio para positivo que se registou neste estudo. Todas as análises 
referentes à densidade de TILs deverão ser replicadas numa coorte alargada e mais 
subpopulações, bem como outras populações imunitárias – como células T 
reguladoras ou linfócitos T gama-delta – deverão ser acrescentadas ao painel. A 
amostra de doentes com metástases cerebrais com origem em cancro da mama 
também deverá ser aumentada e o número de casos deverá ser semelhante entre 
subtipos, de forma a aprofundar o estudo da alteração de status de cada marcador e 
de subtipo molecular. 
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Metástases cerebrais, Microambiente tumoral, Infiltrado linfocitário (TILs), Infiltrado 
linfocitário CD8+ (TILs CD8+), Subtipo molecular.  
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ABSTRACT 
 Brain metastases are more frequent than primary tumours of the brain and 
breast cancer is one of the tumour types with more brain metastization propensity. 
Approximately 15% of women with newly diagnosed metastatic breast cancer will 
develop secondary lesions in the brain. In HER2-amplified and TNBC the brain can 
be first site of metastasis. Tumour-infiltrating lymphocytes, TILs, promising prognostic 
biomarkers in breast cancer, were described in brain metastases, although the brain 
has been considered an immune-privileged site for metastases.  
Therefore, our main goal was to study the prognostic value of total, CD4+ and 
CD8+ stromal TILs in patients with breast cancer brain metastases, using brain 
metastases from immunogenic solid tumours, such as lung cancer, kidney cancer, 
colon cancer and melanoma, as comparators. As secondary objectives, we aimed to 
evaluate the presence of reactive astrocytes; and to assess the expression of PD-L1, 
as it is a predictive marker of benefit from immunotherapy. In parallel, we compared 
breast cancer and respective brain metastases patient tissue samples to assess a 
possible molecular subtype switch. 
 A positive and significant correlation between CD8+ TILs in the stroma and 
overall survival was found when analysing all tumours together. CD4 and PD-L1 
staining were rare events in this study. However, PD-L1 was particularly up-regulated 
in brain tropic TNBC clones, amongst a panel of different breast cancer cell lines. 
Reactive astrocytes were not observed. Alterations in molecular subtype between 
primary tumours and secondary lesions were observed (10/19, 52.6%). 
 Overall, this project gives some input on T-cell infiltrates and their relevance in 
brain metastases from various types of tumours. It reinforces the importance of 
studying TILs subsets pointed out by several studies as crucial to understand their 
different associations with prognosis and progression in brain metastases and other 
tumour types. Immune microenvironment research is at the forefront of cancer 
research and this project raises awareness on the importance of studying immune 
profiles even when the immune system is thought not to have impact on the tumour 
and its secondary lesions, like in breast cancer. 
 
KEYWORDS 
Brain Metastases, Immune microenvironment, Tumour-infiltrating lymphocytes (TILs), 
CD8+ TILs, Molecular subtype.
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1 INTRODUCTION 
 Cancer is one of the main causes of death worldwide and the number of new 
cases is on the rise globally, which represents a major impact on society. The World 
Health Organization (WHO) estimates a number of incident cases of 18.1 million in 
2018 for all cancers, all ages and both sexes, with 0.5 million new cases across the 
world this year. According to WHO, incidence will increase to 29.5 million in 2040. 
These data were obtained from the Global Cancer Observatory (GCO) web-based 
platform (https://gco.iarc.fr/tomorrow/home), consulted in 10 November 2018. 
 Cancer cells can spread from the primary cancer locally, regionally and to 
distant sites. The formation of new tumours in parts of the body other than the site 
where they first formed is called metastases. Although metastases can form in most 
any part of the body, different types of cancer are more likely to spread to certain 
areas than others. Brain metastases (BrMets), or secondary brain tumours, are 
thought to have an incidence higher than 9% to 17% based on various studies, and 
the tumour types that more frequently metastasize to the brain are breast cancer 
(BC), lung cancer, melanoma, colon cancer and kidney cancer1. Metastatic cancer to 
the brain has a poor prognosis, with an average survival of less than 6 months2,3. 
  
1.1 Brain Metastases 
 BrMets are one of the most frequent and devastating neurological 
complications related to systemic cancer, thus representing a significant cause of 
morbidity and mortality1,4,5. They are the commonest intracranial tumours, surpassing 
primary brain tumours. Despite that, there are no available data from the International 
Agency for Research on Cancer (IARC) neither other large-scale studies examining 
the incidence and prevalence of BrMets6. In Portugal these epidemiological data are 
also lacking. Most BrMets originate from lung cancer (36-64%), BC (15-25%) and 
melanoma (5-20%), which together account for 67% to 80% of all cancers7. Also, in 
up to 15% of patients with presentation of BrMets, these will correspond to a 
diagnosis of cancer of unknown primary (CUP)5. 
 BrMets have traditionally been managed with whole-brain radiation therapy 
(WBRT) or stereotactic surgery, and are typically associated with a poor prognosis3. 
Still, early detection and improvements in the treatment of primary tumour and 
systemic disease over the past decades resulted in the increase of survival of 
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patients with BrMets8,9. However, the frequency of the diagnosis of BrMets appears 
to be increasing also, occurring in 20% to 40% of patients with cancer in the United 
States of America1,10. The increased rate of diagnosis and lack of effective therapies 
are of significant concern and turn BrMets in a burgeoning clinical challenge. In view 
of these facts and in order to improve patients’ outcomes, it is clear that there is a 
need to better understand the brain’s milieu in the context of metastatic disease. 
 
1.1.1 Breast Cancer Brain Metastases 
 BC is the most prevalent cancer in women worldwide, and approximately 15% 
of women with newly diagnosed metastatic BC will develop BrMets. However, this 
percentage is referring only to clinically apparent cases, since autopsy studies reveal 
that the incidence may be higher11. 
 BC is a heterogeneous disease divided into different molecular subtypes with 
clinical implications, according to the status of molecular markers such as oestrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 
type-2 (HER2) and Ki67, a proliferation marker12. It is classified as Luminal A (ER+, 
HER2-, PR high, Ki67 low), Luminal B HER2- (ER+, HER2-, PR low or Ki67 high), 
Luminal B HER2+ (ER+, HER2+, any PR, any Ki67), HER2-Amplified (HER2+) 
(HER2+, ER and PR absent) or Triple Negative Breast Cancer (TNBC) (ER and PR 
absent, HER2-). 
 Patients with TNBC and HER2+ BC are at highest risk for central nervous 
system (CNS) recurrence, and incidences of breast cancer brain metastases 
(BCBrMets) as high as 30% to 40% have been reported for these molecular 
subtypes13,14,15,16. Retrospective studies have shown that BC subtype impacts 
survival in patients with BCBrMets, being TNBC the subtype with the poorest 
prognosis17,18. Median survival from the diagnosis of BCBrMets historically ranges 
between 2 and 16 months, depending on the involvement of the CNS, the extent of 
extracranial metastatic disease, performance status and administration of local or 
systemic therapy19,20. Differences in disease progression in patients with BCBrMets, 
which translate into different outcomes, highlight the need for a tailored approach in 
the care of these patients. 
 Despite the report of controversial results in published studies, the small size 
of many of the cohorts used and the little known about the following topic, compelling 
evidence has shown that there are molecular changes occurring in extracranial BC 
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metastases that could make a difference to treatment21,22. The selection of HER2+ 
clones in 24% to 48% of the cases, of ER negative clones in 7% to 13% of the cases 
or of PR negative ones into positive in the metastasis are alterations that could 
enable the prescription of treatments in the metastatic setting that were not an option 
for the primary tumour23,24,25.  
 As previously mentioned, there is a need to know the brain microenvironment 
and to unravel the crosstalk between this particular metastatic niche and tumour 
cells. In the context of BC and other brain tropic tumours, this could provide new and 
more efficient therapeutic strategies in the future. 
 
1.2 Brain Microenvironment 
 Organotropism or the propensity of tumour types to disseminate to specific 
organs, such as the brain, has always been a hot topic in cancer research26. It is 
consensual that tumour cells will grow in congenial environments and that cancer 
cells acquire specialised functions to overtake specific organs, but is still not well 
understood how the metastatic niche is pre-conditioned by the tumour cells in the 
micro- to macrometastases progression. However, it is known that for the brain 
metastatic process there is the formation of perivascular niche, at least at early 
stages, which has been associated with stem-like and resistant cellular phenotype 
per se in brain tumours27,28.  The blood-brain barrier (BBB) components are the most 
likely candidates to provide this supportive niche for cancer cells29. The composition 
of tumour microenvironment depends on the tumour site, meaning that the brain 
microenvironment is different from that of extracranial sites30. It consists of various 
specialised cell types, such as brain endothelial cells, astrocytes and glial cells that 
may influence tumour growth (Figure 1).  Finally, the presence of immune cells has 
been described in metastatic solid tumours to the brain, such as BC, lung cancer and 
melanoma, although their prognostic significance remains unclear31.  
 Overall, it seems that the dissemination of cancer cells to the brain results 
from a symbiotic relationship between the tumour cells and the host, thus it is critical 
to elucidate the underlying molecular features of the metastatic cascade to further 
study and develop more effective therapy modalities that may interfere in this 
relationship, such as immunotherapy5,7. As the tumour microenvironment may deeply 
impact on the efficacy of cancer immunotherapies, the histologic assessment of 
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tumours and their immune contexture is becoming decisive. Quantifying and 
characterising the immune infiltrate, and assessing the presence of prognostically 
relevant cell subsets, such as CD8+ T cells, as well as determining the existence of 
actionable immunotherapy targets, as programmed cell death-ligand 1 (PD-L1), 
represent a new era in the clinical management of BrMets, namely in melanoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Blood-Brain Barrier 
 The brain has been considered an immune-privileged site for metastases, a 
‘sanctuary’ where cancer cells can lay dormant in the CNS, behind the BBB10,32. The 
BBB has a protective role of the brain and is formed by three main types of cells – 
endothelial cells, astrocytes, and pericytes – that limit the invasion of the brain 
parenchyma by circulating molecules, immune cells and antibodies33,34. 
 However, any disseminated tumour may be able to subvert the BBB and reach 
the brain, mainly the brain parenchyma1. Gene expression analysis revealed that 
specific genes, like α2, 6-sialyltransferase (ST6GALNAC5), mediate cancer cell 
passage through it35,36. The expression of ST6GALNAC5 is normally restricted to the 
brain, but it was found to enhance BC cells adhesion to brain endothelial cells. Along 
Figure 1 | Representation of the brain metastatic 
microenvironment. The tumour cells interact with different cell 
types, such as astrocytes, neurons, microglia, and 
oligodendrocytes. Adapted from 
102
. 
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with cycloxygenase-2 (COX2) and other genes, ST6GALNAC5 mediates BC cells 
infiltration through the BBB. 
Furthermore, debate continues as to what extent therapeutic resistance is 
related to inadequate delivery of drugs to the brain versus intrinsic tumour resistance 
and/or stromal protective effects37. 
 
1.2.2 Astrocytes 
 Astrocytes are non-proliferative cells in the normal adult brain that control 
homeostatic functions in health and disease. They can be activated upon injury and 
be involved in gliosis, characterised by proliferation or hypertrophy of several types of 
glial cells or, in its most extreme form, glial scar formation38. They then assume a 
reactive hypertrophic phenotype, characterised by the upregulation and 
rearrangement of the glia-specific cytoskeletal intermediate filament protein glial 
fibrillary acidic protein (GFAP)39,40. Hypertrophic activated astrocytes have been 
associated with BrMets as BrMets can induce the strong local activation of 
astrocytes41. In fact, accumulation of microglia and activated astrocytes around and 
within lesions has been shown, with astrocytes having direct contact with cancer 
cells42,43. 
 As the most abundant cell type in the CNS, astrocytes account for the majority 
of the interactions that cancer cells will be exposed to during brain metastatic 
process, both in early and late stages, and are emerging as essential regulators of 
BrMets progression as they have a secretory nature and can function as oncogenic 
signals for the tumour cells38,41,44. However, it has been reported that they show 
different roles, depending on the stage of the disease44. Overall, initially astrocytes 
act as an innate host defense system preventing disease progression, while in late 
stages they can favour it, providing protection against tumour cell death45,46.  
 
1.2.3 Tumour-Infiltrating Lymphocytes (TILs) 
 Supporting evidence of the role played by immune infiltrating cells in brain 
tumours is increasing, although the CNS being allegedly considered an immune-
privileged site. Despite brain’s apparently limited capacity for inflammatory response, 
BrMets contain tumour-infiltrating lymphocytes (TILs), drivers of the ‘selective 
pressure’ on CNS tumours, in the tumour stroma and in an intratumoral location47.  
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 TILs, which include T and B cells at a density that varies according to tumour 
type and stage of the disease, can be a clinically significant prognostic biomarker in 
various types of tumours48. Their presence in tumours is generally a good prognostic 
sign and despite their role in BrMets being still not clear with conflicting data from 
different primary tumour sites, reviews of the literature concluded that TILs density in 
CNS metastases was strongly associated with improved overall survival 
(OS)49,50,51. 
 BC has not been traditionally considered an immunogenic cancer type. 
Nevertheless, increasing evidences suggest that an effective immune response may 
greatly impact on the clinical behaviour of this malignancy. Also in BC, TILs are 
associated with favourable prognosis, especially in early TNBC and HER2+ BC 
phenotypes – the ones with more brain tropism –, and may positively influence the 
response to systemic therapies52,53. Studies with the same cutoff for TILs positivity 
suggested survival benefit in TNBC patients in their presence54,55. 
 It is extremely difficult to characterise and quantify all TILs subpopulations, 
and the prognostic value of a specific subset may well not represent the total impact 
of TILs on survival, as TILs subsets have their own roles in the immune 
microenvironment and in metastatic BC. For example, CD4+ T cells include helper T 
(Th) and regulatory T (Treg) cells, whereas CD8+ lymphocytes are the main immune 
effector cells. The prognostic value of CD8+ T cells varies according to tumour type 
and, therefore, more prospective studies are warranted to confirm it. However, a 
meta-analysis with 25 studies concluded that high density of CD8+ T cells is an 
indicator of good prognosis in BC patients56. Furthermore, an association between 
higher amounts of CD8+ lymphocytes within the invasive margin and significantly 
longer disease-free survival (DFS) was reported in BCBrMets57. The study of the 
CD4+/CD8+ TILs ratio may be an important parameter in cancer patients. Although it 
varies between different types of cancer, an increase has been observed in patients 
with several cancers, such as BC58,59. 
 
1.2.4 Programmed Cell Death-Protein 1 (PD-1)/Programmed Cell Death-Ligand 
1 (PD-L1) Axis 
The effectiveness of immune-modulating agents within the CNS could be 
limited. However, there is growing evidence that immune therapies may be effective, 
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namely in patients with BrMets from melanoma, providing durable clinical 
responses60. In primary CNS tumours, a study showed promising preclinical data with 
immune-modulating antibodies61. Several lines of evidence suggest that T cells within 
the tumour microenvironment are the drivers of  response to immune-modulation 
therapies47,62. 
 Programmed cell death-protein 1 (PD-1), also known as CD279 (cluster of 
differentiation 279), helps regulating the autoimmune response by down-regulating 
the immune system and suppressing T-cell inflammatory activity. However, this can 
also suppress antitumour immunity. PD-1 is normally expressed on the surface of 
immune cells, but recent studies revealed a widespread tumour-intrinsic expression 
of PD-1 in cancer, such as melanoma and lung cancer63,64. 
 PD-L1, also known as CD274 (cluster of differentiation 274) or B7-H1 (B7-
Homolog 1), similar to programmed cell death-ligand 2 (PD-L2 or PDCD1LG2), is a 
PD-1 ligand and an immune regulatory transmembrane protein expressed by tumour 
cells65. Therefore, targeting the PD-1/PD-L1 axis, by blocking it, is associated with 
tumour regression in several malignancies (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 It has been described that a high level of PD-L1 expression in tumour cells 
correlates with poor prognosis in several cancers, including breast, lung and renal 
Figure 2 | Schematic representation of the PD-1/PD-L1 axis. T cells are deactivated upon 
PD-1 and PD-L1 interaction and activated when inhibitors block this interaction. Adapted 
from 
103
. 
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cancers, and melanoma66. However, other studies have suggested a positive or 
inexistent correlation between PD-L1 expression and survival67,68,69. Specifically in 
BC, PD-L1 was shown to be most frequently expressed in basal-like tumours, though 
its expression was rare70. Thus, its prognostic value is controversial. Finally, a recent 
study defined PD-L1 and PD-L2 expression as a common occurrence in BCBrMets, 
irrespective of primary tumour or BCBrMets phenotypes71. The role played by PD-L2 
is still not clear66. 
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2 OBJECTIVES 
 The primary objective of this project was to retrospectively investigate if the 
immune compartment of BCBrMets, characterised by the presence of stromal TILs 
(total, CD4+ and CD8+), was associated with OS as endpoint, using a randomised 
retrospective cohort of patients with BrMets from other tumours as comparator. 
 As secondary objectives we proposed to: a) characterise the presence of 
activated astrocytes (using GFAP as a surrogate marker) and the expression of PD-
L1 in BCBrMets, and to explore a possible association with the patients’ outcome; b) 
assess the molecular alterations between primary breast tumours and paired BrMets, 
namely in ER, PR, HER2 and Ki67 expression.  
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3 MATERIALS AND METHODS 
3.1 Clinical Samples 
 In this study we used a retrospective cohort of 56 formalin-fixed, paraffin-
embedded (FFPE) samples from BrMets tissue. The use of tissue samples was 
approved by the institutional review board of Hospital de Santa Maria – Centro 
Hospitalar Universitário Lisboa Norte (HSM – CHULN) (approval number 556/14). All 
tissue samples used were initially obtained for pathological diagnosis and are part of 
the general sample archive of the Neuropathology Laboratory, HSM – CHULN. The 
requirement for written informed consent was waived due to the retrospective nature 
of the study. During the analysis, the observers were fully blinded for patients’ 
personal data, as samples were identified by their registration number and, in a later 
phase, by their tissue microarrays (TMAs) positioning.  
 The cohort included 56 patients diagnosed with BrMets between 2009 and 
2013 and followed at Department of Medical Oncology of HSM – CHULN; 34 (60.7%) 
women and 22 (39.3%) men, with a median age at BrMets diagnosis of 58.50 years 
(range 28-90 years), and with BrMets arising from BC (n=25, 44.7%), lung cancer 
(n=15, 26.8%), colon cancer (n=6, 10.7%), kidney cancer (n=6, 10.7%) and 
melanoma (n=4, 7.1%). The time between first recurrence and metastization to the 
brain varied between 0 – 5 BC patients had the brain as primary site of recurrence – 
and 24 months. The median survival after BrMets was 7.5 months. All of the patients 
received holocranial radiotherapy after surgical resection. Sample distribution per 
analysis is represented in Figure 3. 
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Figure 3 | Flowchart of sample distribution per analysis. 
 
3.2 Haematoxylin and Eosin Staining (H&E) 
 For Haematoxylin and Eosin staining (H&E), 5 m sections of TMAs were 
depparafinized in xylene, rehydrated in decreasing concentrations of ethanol (100%, 
95%, 70%); each for 5 minutes (min) and placed in distilled water. Tissue sections 
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were stained with Harris Haematoxylin for 3 min, washed in running tap water for 5 
min, and dipped in 70% ethanol. After staining with alcoholic eosin, tissue sections 
were dehydrated in increasing concentrations of ethanol, cleared in xylene for 10 min 
and mounted with a solvent-based mounting media, Quick-D (Klinipath). 
 
3.3 Immunohistochemical Staining (IHC) 
 For immunohistochemistry (IHC), 5 m sections of TMAs were processed 
using the PT Module Thermo Scientific for Tissue Specimens (Dako), with Antigen 
Retrieval pH 6.0 or pH 9.0 solution (Dako) at 94ºC for 20 min. Sections were washed 
with Phosphate Buffered Saline (Sigma) with 0.05% Tween 20 (VWR, PROLABO) 
(PBS-T) for 5 min at room temperature (RT). The activity of endogenous peroxidase 
was blocked with Blocked Endogenous Peroxidase Solution (Dako) for 10 min at RT, 
followed by three 5 min rinses in wash buffer. Total protein blockade was performed 
using Protein Block Solution (Dako) for 20 min at RT, followed by incubation with the 
following primary antibodies, diluted in Antibody Diluent (Dako): anti-CD4, anti-CD8, 
anti-GFAP, anti-HER2, anti-ERα, anti-PR and anti-Ki67 (for additional details and 
working conditions see Table 1). Tissue sections were rinsed in wash buffer two 
times, 10 min each, and incubated with the visualisation system Dako REAL 
EnVision Detection System, Peroxidase/DAB+, Rabbit/Mouse (Dako) for 1 hour (h) at 
RT. After incubation, slides were rinsed in wash buffer as described above, incubated 
with 3,3'-diaminobenzidine (DAB+ Chromogen, Dako REAL), and rinsed in PBS-T 
and Elix water, each for 5 min. Slides were counterstained with Harris Hematoxylin 
for 10 seconds (sec), washed in running water for 5 min, dehydrated, cleared and 
mounted as described for H&E staining. 
 PD-L1 staining was performed at Instituto de Patologia e Imunologia Molecular 
da Universidade do Porto (IPATIMUP), using the Ventana BenchMark XT Staining 
System, with a 36 min incubation time for the monoclonal mouse anti-human PD-L1 
(1:70) (22C3, Dako) and the OptiView DAB IHC Detection Kit (Ventana Medical 
Systems). Membranous and cytoplasmic staining pattern was expected. 
 The absence of primary antibody was used as negative control for all the 
markers. 
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Table 1 | Antibodies and respective conditions used for the IHC staining in the present study. 
 
Antibody 
Manufacturer 
Clone 
Expected 
Staining Pattern 
Conditions 
Monoclonal mouse 
anti-human CD4  
Dako  
4B12 
Membranous 
 
pH 6.0 
1:100 
1 h at RT 
5 min DAB  
 
Monoclonal mouse 
anti-human CD8 
Dako 
C8/144B 
Membranous and 
Cytoplasmic 
 
pH 6.0 
1:100 
1 h at RT 
5 min DAB 
 
Monoclonal mouse 
anti-human GFAP 
Dako 
6F2 
Cytoplasmic 
 
pH 6.0 
1:100 
1 h at RT 
1 min DAB 
Monoclonal rabbit 
anti-human ERα 
Dako 
EP1 
Nuclear 
 
pH 9.0 
Ready-to-use 
1 h at RT 
5 min DAB 
 
Monoclonal rabbit 
anti-human PR 
Ventana 
1E2 
Nuclear and 
Membranous  
 
pH 9.0 
Ready-to-use 
1 h at RT 
5 min DAB 
 
Polyclonal rabbit 
anti-human 
HER2/ErbB2 
Cell Signaling 
Technology 
NA 
Membranous 
 
pH 9.0 
1:50 
ON at 4ºC 
5 min DAB 
Monoclonal mouse 
anti-human Ki67 
Dako 
MIB-1 
Nuclear 
 
pH 9.0 
1:100 
1 h at RT 
5 min DAB 
   
   h, Hour; RT, Room Temperature; min, Minute(s); NA, Not Applicable; ON, Overnight; ºC, Degree Celsius. 
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3.4 Histological Evaluation and IHC Scoring 
 All H&E and IHC slides were analysed by a Pathologist, with each case being 
represented by 3 cores. The evaluation and scoring of every biomarker resulted from 
the mean of the 3 corresponding cores per case. TILs density was presented as the 
percentage of total TILs in the tumour stromal compartment using visual assessment 
of H&E-stained TMAs. Samples were classified as: absent (0% TILs), slight (30% 
TILs), moderate (30%> TILs 60%), and marked (>60% TILs)72. CD4+ TILs and 
CD8+ TILs were classified as described for TILs after IHC staining and percentages 
were normalised to total stromal TILs.  
 PD-L1 expression was classified as positive (membranous and cytoplasmic 
staining in ≥1% of tumour cells or stromal TILs) or negative (membranous and 
cytoplasmic staining in <1% of tumour cells or stromal TILs)73. 
GFAP was used as a marker of reactive astrocytes. Astrocytes in tumour 
sections were classified qualitatively as not altered (normal GFAP cytoplasmic 
staining intensity) or altered (abnormal GFAP cytoplasmic staining intensity).  
 Hormone receptors (ER and PR), HER2, and Ki67 were classified according to 
the guidelines of the Template for Reporting Results of Biomarker Testing of 
Specimens from Patients with Carcinoma of the Breast, from the College of American 
Pathologists (2014). ER and PR were considered positive if ≥1% positive cells. For 
HER2, staining intensity was classified from 0 to 3: (0) absence of staining, (1) weak, 
(2) moderated and (3) strong staining, and samples were classified as negative (0 or 
1+), equivocal (2+) or positive (3+). Ki67 was classified as low (<10% positive cells), 
borderline (20%-30% positive cells) or high (>30% positive cells). 
 
3.5 Statistical Analysis 
 For statistical analysis, patients were dichotomised into low and high, 
according to TILs and CD8+ TILs percentage cutoff, selected using 12-months OS as 
endpoint and Cutoff Finder (http://molpath.charite.de/cutoff/)74. 
 Demographic and clinicopathologic data of patients were described using 
frequencies for categorical variables, and central tendency and range for continuous 
variables. Univariate association of these characteristics and TILs and CD8+ TILs 
percentage was done through Kruskal-Wallis test, Fisher’s exact test, χ2 test and 
Mann-Whitney test as applicable. OS was estimated using Kaplan-Meier curves and 
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differences were determined using the log-rank (Mantel-Cox) test. A significance 
level of P-value <0.05 was set for all statistical analyses. 
 Statistical analysis was carried out using the software GraphPad Prism 6 for 
Windows (GraphPad Software). 
 
3.6 Cell Culture 
 All cell lines were cultured in supplemented Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco) with 10% (v/v) fetal bovine serum (FBS) (Gibco) and 1% 
(v/v) Penicillin Streptomycin (Pen Strep, 10,000 Units/mL Penicillin, 10,000 μg/mL 
Streptomycin) (Gibco). Cells were kept at 37ºC with 5% CO2 in a humidified 
atmosphere, and medium was changed every two or three days. 
 The BC brain tropic cell lines MDA-MB-231-BR HER2+ and MDA-MB-231-BR 
HER2- were kindly provided by Patricia S. Steeg and David Lyden Lab, at Cornell 
University. MCF-10A, MDA-MB-231, MDA-MB-435S, MCF7, ZR-75, SK-BR-3, MDA-
MB-361 and PC-3 cell lines were purchased from ATCC. MDA-MB-231-BO2, T-47D 
and BT-474 cells were provided by Phyllippe Clézardin Lab, Institut National de la 
Santé et de la Recherche Médicale (INSERM). 
 
3.7 RNA Extraction, cDNA Synthesis and Reverse Transcription - Quantitative 
Polymerase Chain Reaction (RT-qPCR) 
 Ribonucleic Acid (RNA) extraction (NZY Total RNA Isolation kit, NZYtech) was 
performed according to the manufacturer’s protocol. Total RNA was quantified by 
spectrophotometry, using NanoDrop ND-1000 (Thermo Fisher Scientific) and 1 μg of 
total RNA was used to synthesize complementary DNA (cDNA), with Oligo(dT)18 
primer and the NZY M-MuLV First-Strand cDNA Synthesis Kit (NZYTech), according 
to the manufacturer’s instructions. 
 Genes of interest were amplified by semi-quantitative real time PCR in the ViiA 
7 Real-Time PCR System (Applied Biosystems), using specific primers (Invitrogen, 
Table 2) in a 10 μL reaction volume with SYBR Green PCR Master Mix (Applied 
Biosystems). 
 Target gene expression was normalised against the housekeeping gene 
GAPDH, and data were analysed using the 2-ΔΔCt method. 
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Primer 
 
Sense 
(5´-3´) 
 
 
Anti-sense 
(5´-3´) 
 
GAPDH 
 
CAATGACCCCTTCATTGACC 
 
TGGATTTCCATTGATGACA 
 
PD-1 
 
CGTGGCCTATCCACTCCTCA 
 
ATCCCTTGTCCCAGCCACTC 
 
PD-L1 
 
AAATGGAACCTGGCGAAAGC 
 
GATGAGCCCCTCAGGCATTT 
 
PD-L2 
 
GTCTTGGGAGCCAGGGTGAC 
 
TGAAAAGTGCAAATGGCAAGC 
Table 2 | Specific primer sense and anti-sense sequences used for gene amplification. 
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4 RESULTS AND DISCUSSION 
4.1 Prognostic Role of Stromal TILs and CD8+ TILs in BrMets 
 Histologic assessment of the immune context of tumours has been showing 
prognostic relevance75. Thus, the determination of the amount of immune infiltrate as 
well as its composition, in particular of prognostically relevant immune cell subtypes 
such as CD8+ T cells, for example, is becoming central. 
 As stated before, TILs and CD8+ TILs have been shown to have prognostic 
value across a broad range of tumour types and to be positively correlated with OS, 
suggesting that TILs might reduce metastatic spread48,50,51,54. Therefore, as a primary 
objective we aimed to quantify total, CD4+ and CD8+ stromal TILs in BCBrMets, and 
to assess their prognostic role in the context of brain metastatic disease. 
 Although we focused on BCBrMets, we used a retrospective cohort of FFPE 
TMAs, which included not only samples from BCBrMets but also from BrMets from 
other types of tumours. This allowed us to use these non-breast cancer samples as 
comparators in our analysis, enriching the results of this project. Demographic and 
clinicopathological characteristics of the 56 patients with BrMets, included in this 
study, 25 of which with BCBrMets, are presented in Tables 3 and 4, respectively. For 
the analysis of total TILs and CD8+ TILs on H&E and IHC tissues, respectively, we 
excluded 1 case due to absence of tumour in the TMAs cores used for H&E staining. 
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Table 3 | Demographic and clinicopathological 
characteristics of the 56 patients with BrMets originated 
from breast, lung, colon, kidney cancer and melanoma 
included in this study. 
Total (N=56) 
        Age at diagnosis of BrMets (years)   
             Median 58.50         
             Range 28-90         
             IQR 15.75         
    
        Gender   
             Female 34 (60.7%)         
             Male 22 (39.3%)         
    
        Primary tumour   
             Breast cancer 25 (44.6%)         
             Lung cancer 15 (26.8%)         
             Colon cancer 6 (10.7%)         
             Kidney cancer 6 (10.7%)         
             Melanoma 4   (7.2%)         
    
        Time between BrMets and death (months) 
             Median  7.5         
             Mean  11.07         
             Range 1-72         
    
        Survival status   
             Deceased 54 (96.4%)         
             Alive 2 (3.6%)         
    
BrMets, Brain Metastases; IQR, Interquartile Range. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
Total (N=25)
        Age at diagnosis of BrMets (years)
             Median 57
             Range 28-86
             IQR 17
        Gender
             Female 25 (100%)
             Male 0 (0%)
        TNM stage
             IA 2      (8%)
             IB 1      (4%)
             IIA 7    (28%)
             IIB 4    (16%)
             IIIA 4    (16%)
             IIIB 3    (12%)
             IIIC 1      (4%)
             IV 0      (0%)
             Unknown 3    (12%)
        Histology
             Ductal carcinoma 18    (72%)
             Lobular carcinoma 1      (4%)
             Unknown 6    (24%)
        ER statusⱡ
             Positive   7    (28%)
             Negative 16    (64%)
             NA   2      (8%)
        PR statusⱡ
             Positive 11    (44%)
             Negative 12    (48%)
             NA  2      (8%)
        HER2 statusⱡ
             Positive 10    (40%)
             Negative   9   (36%)
             Equivocal   4    (16%)
             NA   2      (8%)
        Ki67 statusⱡ
             High  8    (32%)
             Low 5    (20%)
             Borderline 10    (40%)
             NA 2      (8%)
        Molecular subtype* Primary tumour Metastasis
             Luminal 9 (36%)  7    (28%)
             Luminal B HER2+ 3 (12%) 5    (20%)
             HER2+ 7 (28%) 6    (24%)
             TNBC 2   (8%) 5    (20%)
             Unknown 4 (16%) 0      (0%)
             NA 0   (0%) 2      (8%)
        Molecular subtype discordance
        between primary tumour and metastasis
        Unknown 4/25     (16%)
        NA 2/25       (8%)
        Adjuvant therapy 25  (100%)
   BrMets , Brain Metastases; IQR , Interquartile Range; ER , Oestrogen Receptor; PR , Progesterone Receptor;
   HER2 , Human Epidermal Growth Factor Receptor type-2; TNBC , Triple Negative Breast Cancer;
   NA , Not Applicable, meaning absence of tumour or loss of > 50% of the cores.
   ⱡSatuses  refer to the metastasis; *Molecular subtype classification is according to the 2015 St Gallen
   Consensus Conference, recommended by the ESMO Clinical Practice Guidelines; Luminal comprises
   Luminal A and Luminal B HER2- subtypes.
10/19 (52.6%)
Table 4 | Demographic and clinicopathological characteristics of the 25 
patients with BCBrMets included in this study. 
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TMAs H&E slides were used to observe tissue morphologic characteristics 
and also to quantify total TILs (Figure A1). Next, samples were dichotomised into low 
or high TILs, using the cutoffs 1%, 3% and 0.5% for BC cases, non-BC cases and all 
tumour types, respectively, as these were the best cutoff points found by Cutoff 
Finder after testing other cutoffs (median; positive (>0) vs negative (0)). These cutoffs 
were not close to the 50% cutoff point reported as the best for dichotomisation of 
lymphocyte-predominant BC, due to overall low TILs density in our TMAs samples. 
Moreover, 50% was chosen to analyse only lymphocyte-predominant BC, a subset of 
TNBC and we had only five TNBC samples in our fifty six tissue samples cohort53. 
CD4+ and CD8+ TILs were assessed by IHC and normalised to total TILs 
(Figures A2 and A3, respectively). Next, samples were dichotomised into low or high 
TILs, using the cutoffs 75%, 45% and 45% for BC cases, non-BC cases and all 
tumour types, respectively, like in TILs. Representative images of H&E and IHC 
staining are displayed in Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 | Representative tissue sections with high or low total or CD8+ 
TILs in tissue samples from patients with BrMets from BC (A) and non-
BC tumours (B). Example of TILs on H&E sections is indicated by a white 
circle; Example of CD8+ TILs in IHC sections is indicated by a black circle. 
Magnification X200. 
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Across all samples, total TILs ranged between 0% and 30%, corresponding to 
absent or slight TILs, respectively (Figure 5). Median TILs ranged between 1.33% 
and 8.33%, depending on tumour type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 | Total TILs in BrMets according to the origin of the primary tumour (A) and comparing 
metastases from BC with metastases from non-breast tumours (B). Corresponding mean percentage, 
median percentage and range (%) are registered in the table (C). P-value was calculated with Kruskal-Wallis 
(A) or Mann-Whitney test (B), and significance was set as p<0.05.  
 
Figure 4 | Representative tissue sections with high or low total or CD8+ 
TILs in tissue samples from patients with BrMets from BC (A) and non-
BC tumours (B). Low TILs and CD8+ TILs on the left, high TILs and CD8+ 
TILs on the right. Example of TILs on H&E sections is indicated by a white 
circle; Example of CD8+ TILs in IHC sections is indicated by a black circle. 
Magnification X200. (Continued) 
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Figure 5 | Total TILs in BrMets according to the origin of the primary tumour (A) and 
comparing metastases from BC with metastases from non-breast tumours (B). 
Corresponding mean percentage, median percentage and range (%) are registered in the 
table (C). P-value was calculated with Kruskal-Wallis (A) or Mann-Whitney test (B), and 
significance was set as p<0.05. (Continued) 
 
 Regarding specific subsets of TILs, we observed the presence of both CD4+ 
and CD8+ TILs in BrMets, although CD4 staining was a rare event in this study, with 
only four positive cases. The scarce positive data prevented us from further 
investigating their relevance in this cohort. However, we must take into account that 
CD4+ TILs absence was consistently observed and that this may be of particular 
relevance and deserve further studies in larger cohorts. Moreover, the use of TMAs 
is a limitation of this study, inasmuch as TMAs surely limit the representativeness of 
the tissue heterogeneity.  
 Concerning CD8+ T cells, 23/55 cases (41.8%) scored 100%. Given the low 
percentages of total TILs, this implies that even in those cases of abundant CD8+ 
TILs, they correspond to a small part of the immune cell population. It would be 
important to quantify the other immune cell subpopulations in those BrMets system to 
further characterise the microenvironment of BrMets. 
Distribution of CD8+ TILs across the different types of tumours is depicted in 
Figure 6. As in total TILs, we did not observe a difference between tumour types. 
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Figure 6 | CD8+ TILs in BrMets according to the origin of the primary tumour (A) and comparing 
metastases from BC with metastases from non-breast tumours (B). Corresponding mean 
percentage, median percentage and range (%) are registered in the table (C). P-value was calculated 
with Kruskal-Wallis (A) or Mann-Whitney test (B), and significance was set as p<0.05.  
  
 Since it has been suggested that the ratio CD4+/CD8+ TILs may impact the 
prognosis in melanoma, BC and squamous cell carcinoma of the cervix, we analysed 
the CD4+/CD8+ TILs ratio in the four cases with CD4+ TILs, two from melanoma, 
one from BC and one from lung cancer, even though it did not allow us any statistical 
inference (Figure 7)58,59,76.  
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Melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 | Representative images of tissue sections with the lowest (left) 
and the highest (right) CD4+/CD8+ TILs ratios (bold in the table). TILs are 
pointed out by black arrows. Ratios of the cases with positive CD4 staining. 
Magnification X200. 
  
TILs subsets have their own roles in BC progression and CD8+ TILs, the main 
effective cells in the immune response, have been related to better DFS48,56,77. 
31 
 
T im e  a fte r  m e ta s t iz a t io n  (m o n th s )
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
0 5 0 1 0 0 1 5 0
0
5 0
1 0 0 B re a s t        (n = 2 4 )
N o n -b re a s t (n = 3 1 )
p  =  0 .0 2 9 2
*
H R  =  0 .5 8 0 3
(0 .2 9 9 5  -  0 .8 8 3 9 )
T im e  a fte r  m e ta s t iz a t io n  (m o n th s )
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
0 5 1 0 1 5 2 0 2 5 3 0
0
5 0
1 0 0
9 0 1 2 0 1 5 0
p  =  0 .0 2 7 5
*
L u n g          (n = 1 5 )
C o lo n         (n = 6 )
K id n e y       (n = 6 )
M e la n o m a  (n = 4 )
B re a s t (n = 2 4 )
T im e  a fte r  m e ta s t iz a t io n  (m o n th s )
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
0 5 1 0 1 5
0
5 0
1 0 0 B re a s t (n = 2 4 )
p  =  0 .0 8 3 7
L u n g          (n = 1 5 )
C o lo n         (n = 6 )
K id n e y       (n = 6 )
M e la n o m a  (n = 4 )
So next we aimed to assess the prognostic role of total TILs and CD8+ TILs in 
BrMets, by quantifying its association with OS. 
 Samples were dichotomised into low and high TILs and CD8+ TILs according 
to best cutoff value when analysing OS as endpoint. The exception was the sub-
analysis of TILs in BCBrMets, where we could not use Cutoff Finder, and selected 
the median as dichotomisation cutoff, since it was the method tested associated with 
the best P-value. 
 We started by assessing the contribution of the primary tumour type to survival 
rates and 12-months survival rates (Figures 8 and A4, respectively). The OS curves 
were different according to the tumour type (p=0.0275), and better for BC patients, in 
comparison to non-breast patients (p=0.0292, median survival 11 vs. 7 months). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 | Overall survival according to the origin of the primary tumour and comparing breast with non-
breast metastatic disease (n=56). P-value was calculated using log-rank (Mantel-Cox) test, and significance 
was set as p<0.05.  
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Next we assessed the impact of total TILs and CD8+ TILs on OS (Figures 9 
and 10, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | 12-months-overall survival according to TILs percentage in BrMets from BC (n=24), 
all tumours (n=55), and non-BC (n=31). Cutoff values for dichotomisation (%) 1, 0.5, 3, 
respectively. P-value was calculated using log-rank (Mantel Cox) test, and significance was set as 
p<0.05. 
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Figure 10 | 12 months-overall survival according to CD8+ TILs percentage in BrMets from BC 
(n=24), all tumours (n=55), and non-BC (n=31). Cutoff values for dichotomisation (%) 75, 45, 45, 
respectively. P-value was calculated using log-rank (Mantel Cox) test, and significance was set as 
p<0.05. 
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Our data showed that TILs do not have impact on OS in BCBrMets (p=0.4908, 
median survival undefined vs. 7.5 months), in BrMets from other tumours (p=0.5590, 
median survival 6 vs. 8 months), or in all tumours (breast plus non-breast, p=0.5360, 
median survival 4 vs. 8.5 months), although in this case there was a trend for an 
association between high TILs and better OS. However, CD8+ TILs (Figure 10), were 
significantly associated with better OS in non-BC (p=0.0296, median survival 4 vs. 11 
months) and all tumors (p=0.0495, median survival 6 vs. 11.5 months). In BC, there 
was a trend for an association (p=0.3971, median survival 6.5 months vs. undefined), 
even though no statistical significance was reached. This analysis should be 
repeated in a larger group of patients with BCBrMets, since the immune contexture of 
BC has gained broad acceptance as an important clinical factor correlated with 
patient prognosis, and also therapy prediction in primary tumours78.  
 Overall, our data support that TILs and in particular CD8+ TILs can be 
indicators of a less aggressive disease, since these were positively associated with 
survival. In fact, although the percentage of TILs was consistently low independently 
of tumour origin, the primary tumour was significantly associated with low or high 
TILs, upon dichotomisation (p=0.0014) (Table 5). There was also an association 
between gender and low (male) or high TILs (female) (p=0.0003). Tissues from 
BrMets from lung or skin cancers were predominantly low TILs, whereas in the case 
of breast, colon and kidney cancers the majority of the cases where classified has 
high TILs. It is important to take into account that apart from breast and lung cancer, 
the relative numbers of cases were very small. Moreover, there is a clear role of the 
immune system in lung cancer, and BC is not typically associated with an immune 
enrichment, therefore a cautious interpretation of these data and proper validation is 
required79. Nevertheless, future work should be done in order to study subtype 
immunogenicity of BC. The subcohort of BC should be enlarged to enable the 
assessment of TILs and CD8+ TILs as well as their association with patient outcome 
in the context of molecular subtypes of BC, since variable immunogenicity activity 
has been suggested before80,81. The presence of CD8+ T cells was associated with a 
reduction of hazard of BC-specific mortality, specifically in ER- tumours but not in 
ER+, in which no differences in survival were found concerning CD8+ infiltrate82. 
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Table 5 | Association between clinicopathological characteristics of patients with BrMets originated from 
breast, lung, colon, kidney and melanoma and total and CD8+ stromal TILs. 
 
 
  
Association between high CD8+ TILs and median OS was also significant by 
Mann-Whitney test analysis (p =0.0441) (Table 5).  
 Considering the literature, the relevance of TILs in BrMets is not totally 
unravelled49. The present study describes the percentage of TILs and CD8+ TILs in 
BrMets from different brain tropic primary tumours and data suggest that, widening 
the cohort, the percentages of TILs and CD8+ TILs in the stroma of the BrMets, 
breast and non-breast, in fact can become biomarkers of better prognosis, as in the 
literature. Overall, these results are supported by the literature, that has suggested 
TILs as prognostic biomarkers across different types of cancers, including BC, 
ovarian cancer, Non-Small Cell Lung Cancer (NSCLC) and melanoma48,56,77. It would 
be important to analyse TILs and CD8+ TILs in the respective primary tumours. A 
recent study published in the Annals of Oncology showed that some immune-
oncology targets and macrophage and angiogenesis signatures have preserved 
expression and suggest therapeutic combinations for clinical testing83. In view of 
Clinicopathological characteristics (n=55) Low High p -value Low High p -value
Number of patients 28 27 21 34
Age at diagnosis of BrMets (years) 0.3461 ¥ 0.5674 ¥
     Median 56 60 56 58.5
     Range 40-90 28-86 28-90 40-86
     IQR 13.75 19 16.5 17.5
Gender 0.0003 § 0.7823 §
     Female 10 23 12 21
     Male 18 4 9 13
Primary tumour 0.0014 † 0.9377 †
     Breast cancer 7 (25%)        17 (63%) 9 (37.5%) 15 (62.5%)
     Lung cancer 14 (50%)        1 (3.7%) 5 (33.3%) 10 (66.7%)
     Colon cancer 2 (7.1%)        4 (14.8%) 3 (50%) 3 (50%)
     Kidney cancer 2 (7.1%)        4 (14.8%) 2 (33.3%) 4 (66.7%)
     Melanoma 3  (10.7%)        1 (3.7%) 2 (50%) 2 (50%)
Time between brain relapse and death (months) 0.8840 ¥ 0.0705 ¥
     Median 7 7 5 11
     Mean 10.04 12.27 8.25 12.88
     Range 1-38 1-72 1-38 1-72
12-months OS 0.2518 ¥ 0.0441 ¥
     Median 4 8.5 6 11
Bold indicates p <0.05, meaning statistical significance.
¥ Mann Whitney test; † χ2  test; § Fisher's exact test
BrMets , Brain Metastases; IQR , Interquartile Range; 12-months OS , Overall Survival with 12 months as endpoint.
Stromal TILs Stromal CD8+ TILs
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these findings, to understand if and how TILs and CD8+ TILs vary during tumour 
progression and assess a possible relevance in terms of OS, would pave the way to 
new therapeutic options for BrMets in the future.  
 Furthermore, it is important to mention that we did not perform survival 
analysis adjusting for the different molecular subtypes of BC due to the small sample 
size (n=24). In our study, no association was found between clinicopathological 
features of BC patients and stromal TILs or stromal CD8+ TILs (Table 6). It would be 
interesting to further investigate it, inasmuch as TILs have suggested survival benefit 
in BC patients, namely in TNBC50,56. Moreover, the study of the genomes of the 
surviving cancers, and their comparison between different BC molecular subtypes 
could lead to more efficient therapeutic approaches for each. Finally, one cannot 
neglect the study of stromal TILs and stromal CD8+ TILs, along with other immune 
targets, in the primary lesions, in future studies. It would be strongly advisable to do 
so in order to clarify the role of immune surveillance in primary breast cancers 
regarding clonal heterogeneity and consequently the changes in BC to BC 
metastases immunogenicity. 
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Clinicopathological characteristics (n=24) Low High p -value Low High p -value
Number of patients 18 6 12 12
Age at diagnosis of BrMets (years) 0.7331 ¥ 0.2587 ¥
     Median 56,5 57,5 55 60,5
     Range 28-72 40-86 28-86 46-72
     IQR 16 28 19,75 17,75
TNM stage 1.0000 § 1.0000 §
     I-III 17 (94.4%) 5 (83.3%) 11 (91.7%) 11 (91.7%)
     IV 0 (0%) 0 (0%) 0 (0%) 0 (0%)
     Unknown 1 (5.6%) 1 (16.7%) 1 (8.3%) 1 (8.3%)
ER status ⱡ 0.6158 § 0.3615 §
     Positive   6 (33.3%) 1 (16.7%) 2 (16.7%) 5 (41.7%)
     Negative 10 (55.6%) 5 (83.3%) 9 (75%) 6 (50%)
     NA   2 (11.1%) 0 (0%) 1 (8.3%) 1 (8.3%)
PR status ⱡ 0.6351 § 1.0000 §
     Positive 9 (50%) 2 (33.3%) 5 (41.7%) 6 (50%)
     Negative 7 (38.9%) 4 (66.7%) 6 (50%) 5 (41.7%)
     NA 2 (11.1%) 0 (0%) 1 (8.3%) 1 (8.3%)
HER2 status ⱡ 1.0000 § 1.0000 §
     Positive 8 (44.4%) 3 (50%) 6 (50%) 5 (41.7%)
     Negative 5 (27.8%) 3 (50%) 5 (41.7%) 3 (25%)
     Equivocal   3 (16.7%) 0 (0%) 0 (0%) 3 (25%)
     NA 2 (11.1%) 0 (0%) 1 (8.3%) 1 (8.3%)
Ki67 status ⱡ 1.0000 § 1.0000 §
     High 4 (22.2%) 2 (33.3%) 3 (25%) 3 (25%)
     Low/Borderline   12 (66.7%) 4 (66.7%) 8 (66.7%) 8 (66.7%)
     NA  2 (11.1%) 0 (0%) 1 (8.3%) 1 (8.3%)
Molecular subtype ⱡ * 0.7288 † 0.7288 †
     Luminal  4 (22.2%) 1 (16.7%) 4 (26.7%) 1 (11.1%)
     Luminal B HER2+  4 (22.2%) 1 (16.7%)   4 (26.7%) 1 (11.1%)
     HER2+ 3 (16.7%) 1 (16.7%)       2 (13.2%) 2 (22.2%)
     TNBC  2 (11.1%) 2 (33.2%)    3 (20%) 1 (11.1%)
     Unknown 3 (16.7%) 1 (16.7%)   1 (6.7%) 3 (33.4%)
     NA  2 (11.1%) 0 (0%)  1 (6.7%) 1 (11.1%)
Molecular subtype discordance 1.0000 § 0.6372 §
between primary tumour and metastasis
     Yes 6 (21.4%) 3 (50%) 6 (50%) 3 (25%)
     No 17 (60.7%) 2 (33.3%) 4 (33.4%) 5 (41.7%)
        Unknown 3 (10.7%) 1 (16.7%) 1 (8.3%) 3 (25%)    
     NA 2 (7.2%) 0 (0%) 1 (8.3%) 1 (8.3%)
Time between brain relapse and death (months) 0.8840 ¥ 0.0705 ¥
     Median 7 7 5 11
     Mean 10,04 12,27 8.25        12,88
     Range 1-38 1-72 1-38        1-72
12-months OS 0.6993 ¥ 0.4025 ¥
     Median 12 7,5 6,5 12
p <0.05 means statistical significance.
¥ Mann Whitney test; † χ2  test; § Fisher's exact test
BrMets , Brain Metastases; IQR , Interquartile Range; ER , Oestrogen Receptor; PR , Progesterone Receptor; HER2, Human Epidermal Growth 
Factor Receptor type-2; TNBC, Triple Negative Breast Cancer; NA, Not Applicable, meaning absence of tumour or loss of > 50% of the cores.
ⱡ Statuses and Molecular subtype refer to the metastases; *Molecular subtype classification is according to the 2015 St Gallen Consensus 
Conference, recommended by the  ESMO Clinical Practice Guidelines; Luminal comprises Luminal A and Luminal B HER2- subtypes.
NA , Equivocal  and Unknown  are not taken int account to the statistical test.
Stromal TILs Stromal CD8+ TILs
 
Table 6 | Association between clinicopathological characteristics of patients with BCBrMets and total 
and CD8+ stromal TILs. 
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Finally, we only looked for stromal TILs as they are currently known to be the 
best parameter for characterisation of TILs72. Intratumoural TILs are described by 
several studies as more difficult to evaluate and do not provide additional 
predictive/prognostic value compared to stromal TILs. 
 
4.2 Detection of Reactive Astrocytes in BrMets 
 As a secondary objective of this study, we intended to address the presence of 
reactive (or altered) glial cells, namely astrocytes, as they are the most abundant 
cells on the BrMets microenvironment, and might interact with cancer cells and other 
adjacent cell types44. To detect astrocytes we used the cytoskeletal intermediate 
filament protein GFAP as marker. GFAP is expressed in normal, reactive and 
neoplastic astrocytes35. All BCBrMets tissue sections (n=25) were observed and 
classified by a Pathologist, without GFAP staining intensity alterations (Figure 11). 
This suggests that astrocytes did not suffer phenotypic modifications in this particular 
group of patients. 
 Despite knowing from the literature that GFAP is a glia-specific protein and not 
astrocytes-specific40,84, we expected to observe strong staining intensity, since 
astrocytes are usually characterised by the upregulation of GFAP in any brain 
injury44. Moreover, previous studies of BCBrMets have shown a profusion of 
activated astrocytes around and within the lesions15,41. 
 
4.3 Characterisation of PD-L1 Expression in BrMets 
 Histologic assessment of tumours and their immune microenvironment is 
becoming really relevant in the clinical setting for patients with solid tumours75. Thus, 
Figure 11 | Representative images of tissue sections of BC and normal brain stained for GFAP. Negative 
control (A); BCBrMet sample with glial elements (red arrow) (B); Normal brain parenchyma with stained 
astrocytes (black arrow) and other glial cells, and a blood vessel (*) (C). Magnification X200. 
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we aimed to determine the prevalence of PD-L1, an actionable immunotherapy target 
described to be expressed in some tumour cells63, and to assess its correlation with 
survival outcomes. 
 PD-L1 expression was determined by IHC, and scored by a Pathologist 
according to intensity of staining and percentage of cells per intensity (Figure 12). In 
our cohort of BrMets (n=55), only four cases were positive for PD-L1 expression, with 
modified H-score of 10 for one BCBrMets and 20, 30 and 210 in three lung cancer 
BrMets.  
 
  
 
 
 
 
 
 
 
 
 
 
As mentioned in the Materials and Methods section, the modified H-score 
considers the frequency of positive cells (%) and staining intensity, and it has been 
described that elevated expression of PD-L1 is associated with worse prognosis and 
better response of BC patients to immune treatment85. However, and our data is in 
accordance to this, PD-L1 expression is rare in BC tissues, both in immune and 
tumour cells. Additionally, a significant enrichment of PD-L1 is registered in basal-like 
tumours, and our only positive BC case was in fact a TNBC (1/5 TNBC cases), 
according to the IHC analysis of the metastatic tissue (Table 3)70. The other four 
tumour types, lung cancer, colon cancer, kidney cancer, and melanoma, are known 
to be immunogenic, so we eventually envisaged more positive cases than we 
obtained49,86,87. However, all our tumour-specific subcohorts are small. 
 PD-L1 expression tends to decrease between primary tumours and BrMets 
and varies in BCBrMets according to the subtype of primary lesion88. A lower 
expression of 13/29 selected immune-oncology therapeutic targets in metastases in 
Figure 12 | Representative images of tissue sections immunostained for PD-L1. BC and lung 
BrMets with positive PD-L1 score, with staining intensities of 1+, and 3+, respectively. Magnification 
X200. 
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which PD-L1 was included was found in a recent study83. Along with it, previously 
published data indicate an immune depleted state in metastatic lesions. 
Nevertheless, it is important to stress that the use of TMAs could have impaired 
results of heterogenic markers and underestimated true positivity.  
 Given the small number of positive results obtained, we were not able to 
proceed with further outcome analysis. However, to complement this study, we 
assessed the expression of PD-L1, and also PD-1 and PD-L2 in a panel of cancer 
cell lines, including two brain tropic clones of a TNBC cell line. 
 
4.3.1 Expression of PD-1, PD-L1 and PD-L2 in Cancer Cell Lines 
 In order to quantify the gene expression of PD-1 (PD-1), PD-L1 (PD-L1) and 
PD-L2 (PD-L2) in cancer cell lines by RT-qPCR (Figure 13), we used two brain tropic 
clones from the MDA-MB-231 TNBC cell line, MDA-MB-231-BR HER2+ and MDA-
231-BR HER2-, along with other nine BC cell lines (TNBC: MDA-MB-435S, MDA-MB-
231, MDA-MB-231-BO2; HER2+: SK-BR-3; Luminal A: MCF7 and T-47D; Luminal B 
HER2-: BT-474, MDA-MB-361, ZR-75), and one prostate adenocarcinoma cell line 
(PC-3). The MCF-10A non-malignant mammary epithelial cell line was used to 
normalise the expression values and Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) was used as internal control for gene expression data normalisation. 
 In metastatic BC, there are few preclinical models to study the inherent 
heterogeneity of BrMets89,90. The MDA-MB-231 cell line has been the most broadly 
selected for brain tropism90,91,92, as MDA-MB-231-BR resembles human craniotomy 
specimens in terms of proliferation, apoptosis, and a neuro-inflammatory response43. 
The proteome of this cell line has been compared with that of the parental cell line, 
MDA-MB-231. By means of protein quantitative analysis, a group of researchers has 
determined that 112/152 proteins were decreased and only 40/152 were increased, 
meaning that downregulation of specific proteins can be an important part of the 
underlying mechanism for BC cells to metastasize to the brain93. The Steeg P. 
laboratory has transfected cells with HER2 cDNA or a control vector after transducing 
them with enhanced green fluorescence protein (EGFP) in order to develop the 
MDA-MB-231-BR HER2+ cell line, a model system to study the relevance of HER2 
overexpression in BrMets89. This laboratory has shown that the preclinical model 
mimics many characteristics of human BrMets. 
41 
 
 
 
 
 
 
P D -1
M
C
F
 1
0
A
M
D
A
-M
B
-4
3
5
S
M
D
A
-M
B
-2
3
1
M
D
A
-M
B
-2
3
1
-B
O
2
M
D
A
-M
B
-2
3
1
-B
R
 H
E
R
2
-
M
D
A
-M
B
-2
3
1
-B
R
 H
E
R
2
+
S
K
-B
R
-3
M
C
F
7
T
-4
7
D
B
T
-4
7
4
M
D
A
-M
B
-3
6
1
Z
R
-7
5
P
C
-3
0
2
5
1 0
2 0
2 5
R
e
la
ti
v
e
 m
R
N
A
e
x
p
r
e
s
s
io
n
T N B C  c e ll l in e
L u m in a l  A  c e l l l in e
L u m in a l B c e ll l in e
M a m m a ry  e p ith e lia l c e ll  l in e
P ro s ta te  a d e n o c a rc in o m a  c e ll l in e
H E R 2 +  c e l l l in e
c u to ff  v a lu e , 1 .5
c e ll  l in e  n o rm a liz a t io n
P D -L 1
M
C
F
 1
0
A
M
D
A
-M
B
-4
3
5
S
M
D
A
-M
B
-2
3
1
M
D
A
-M
B
-2
3
1
-B
O
2
M
D
A
-M
B
-2
3
1
-B
R
 H
E
R
2
-
M
D
A
-M
B
-2
3
1
-B
R
 H
E
R
2
+
S
K
-B
R
-3
M
C
F
7
T
-4
7
D
B
T
-4
7
4
M
D
A
-M
B
-3
6
1
Z
R
-7
5
P
C
-3
0 .0
0 .5
1 .0
1 .5
2 .0
3 .0
3 .5
4 .0
4 .5
5 .0
T N B C  c e ll l in e
R
e
la
ti
v
e
 m
R
N
A
e
x
p
r
e
s
s
io
n
M a m m a ry  e p ith e lia l c e ll  l in e
L u m in a l  A  c e l l l in e
L u m in a l B c e ll l in e
H E R 2 +  c e l l l in e
P ro s ta te  a d e n o c a rc in o m a  c e ll l in e
c u to ff  v a lu e , 1 .5
c e ll  l in e  n o rm a liz a t io n
PD-1 
PD-L1 
Figure 13 | PD-1, PD-L1 and PD-L2 expression in a panel of cancer cell lines. PD-1 (A), PD-L1 (B) and 
PD-L2 (C) expression determination was performed by RT-qPCR in MDA-MB-435S, MDA-MB-231, MDA-MB-
231-BO2, MDA-MB-231-BR HER2- (TNBC); MDA-MB-231-BR HER2+, SK-BR-3 (HER2+); MCF7, T-47D 
(Luminal A); BT-474, MDA-MB-361, ZR-75 (Luminal B HER2-) cell lines. Relative expression levels were 
calculated by comparative Ct method and values are presented as fold change (2
-ΔΔCt
) relative to expression 
in the non-tumorigenic MCF10A cell line. GAPDH was used as housekeeping gene. Cutoff value for up-
regulation: 1.5. 
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PD-1 (Figure 13A) was upregulated in all tested cancer cell lines, with the 
exception of ZR-75, and the expression levels were decreased in the brain tropic 
clones when comparing to the parental TNBC cell line MDA-MB-231 and the bone 
tropic clone. PD-1 is described to be only expressed on the surface of immune cells, 
while its ligands, PD-L1 and PD-L2, are found expressed in tumour cells63. However, 
recent studies, which our data are along with, show intrinsic expression of the 
receptor in tumours, such as melanoma, liver cancer or NSCLC63,64.  
 Regarding the ligands, PD-L2 (Figure 13C) was downregulated in all cancer 
cell lines, and PD-L1 (Figure 13B) was exclusively upregulated in the bone and brain 
tropic TNBC clones, particularly in the last ones. This suggests an association 
between the expression of PD-L1 in BrMets and the brain immune microenvironment, 
as we hypothesized at first and despite our results in the clinical cohort. 
 As far as we know, this is the first assessment of the expression of PD-1, PD-
L1 and PD-L2 in the MDA-MB-231-BR HER2+ and MDA-MB-231-BR HER2- brain 
tropic clones, which makes it impossible for us to compare our results with reported 
values. The expression data of these genes was searched in databases, such as 
Figure 13 | PD-1, PD-L1 and PD-L2 expression in a panel of cancer cell lines. PD-1 (A), PD-L1 
(B) and PD-L2 (C) expression determination was performed by RT-qPCR in MDA-MB-435S, MDA-
MB-231, MDA-MB-231-BO2, MDA-MB-231-BR HER2- (TNBC); MDA-MB-231-BR HER2+, SK-BR-3 
(HER2+); MCF7, T-47D (Luminal A); BT-474, MDA-MB-361, ZR-75 (Luminal B HER2-) cell lines. 
Relative expression levels were calculated by comparative Ct method and values are presented as 
fold change (2
-ΔΔCt
) relative to expression in the non-tumorigenic MCF10A cell line. GAPDH was 
used as housekeeping gene. Cutoff value for up-regulation: 1.5. (Continued) 
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Cancer Cell Line Encyclopedia (CCLE) and Oncomine but comparable results were 
not found. 
 
4.4 ER, PR and HER2 Status in Primary Breast Tumours and Matched BrMets 
 It is known that during tumour progression molecular alterations occur due to 
clonal selection of the fittest cancer cells. In BC, metastases are not necessarily 
identical to primary tumours, concerning hormone receptor (HR) and HER2 
expression, which impacts on treatment choice and efficacy. Therefore, whenever 
possible the status of HR and HER2 on metastatic tissue should be determined. 
 In our subcohort of 25 BCBrMets patients the HR, HER2, and Ki67 expression 
was unknown in clinical records, so we proposed to perform these determinations, 
and to verify if there was a molecular switch between primary tumour and metastasis 
(excluding Ki67 expression due to the lack of information on the primary tumour). 
Upon ER, PR, HER2, and Ki67 IHC, samples were evaluated by a Pathologist, and 
classified as Luminal, Luminal B HER2+, HER2+ or TNBC (Figure 14 and Table 4). 
Figure 14 | Representative images of BrMets tissue sections immunostained for ER, PR, HER2 and 
Ki67, corresponding to different molecular subtypes of BC. TNBC: negative ER, PR, HER2 (1+), low 
Ki67; HER2+: negative ER, PR, positive HER2 (3+), low Ki67; Luminal B HER2+: negative ER, positive 
PR, positive HER2 (3+), low Ki67; Luminal: positive ER, PR, negative HER2 (1+), high Ki67. Magnification 
X200. 
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Luminal Luminal B HER2+ HER2+ TNBC
Molecular switch (%) 
10/19 (52.6%)
Molecular
status
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The median age of the patients at metastasis diagnosis was 57 years (range 
28-86 years), and ductal BC was the predominant histologic subtype. Median brain 
metastases-free survival was 15.50 months (IQR=43.25), ranging between 1 and 119 
months and median survival after diagnosis of brain metastasis was 8 months 
(IQR=12), ranging from 1 to 72 months. Survival after brain recurrence depends on 
factors that include, among others, the extent of extracranial disease, performance 
status, and local or systemic therapy administration. Nevertheless, great differences 
in survival after a diagnosis of brain metastases by receptor status have been shown 
in retrospective studies11. In this particular study, we did not analyse survival by 
subtype due the small size of the cohort.  
 In this study we had complete information about the primary tumour and 
metastasis subtype in 19 out of the 24 cases (79.2%). 10/19 cases (52.6%) had at 
least one alteration, comparing the breast tumour and brain metastasis, and all these 
ten cases changed the status of HR (Figure 15). In six cases there was loss of HR, 
and in four cases there was gain in HR expression.  
 
 
 
 
 
 
 
 
 
Figure 15 | Representative schema of the molecular status switch between BC primary tumours 
and paired BrMets. HER2+, Human Epidermal Growth Factor type 2-positive; TNBC, Triple Negative 
Breast Cancer. 
 
 Several studies have shown that expression of HR is not necessarily 
conserved during carcinogenesis and tumour progression. Loss of HR is the most 
common alteration and may be related to clonal selection of less differentiated cells 
during the metastatic process, for example, caused by adjuvant hormonal selective 
pressure94,95. However, conversion from negative to positive HR has also been 
described before96.  
 A lower rate of discordance was found concerning HER2 expression. Only one 
case presented discordance, corresponding to loss of HER2. This is in accordance 
with the literature, since the HER2 status is more stable than that of HR21. Besides, 
from a tumour progression model perspective one would expect HER2 gain, result of 
gene amplification, due to the oncogenic role of this receptor96.  
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 The alterations described above led to a different classification of BrMets 
molecular subtype in comparison with primary tumors (Table 3). Thus, this pairwise 
analysis points out the need to evaluate HR and HER2 statuses in metastases as 
this may impact the treatment choice. For example, in patients whose switch is in the 
direction of HER2 and/or ER positivity (four cases in this subcohort). Moreover, 
compelling evidences suggest that primary and metastatic tumours are different. 
Cancer cells suffer from strong selective pressure and the vast majority is either 
eliminated or kept in a dormant state during metastatic colonisation. The ones that 
evade this selective pressure are able to manipulate the local microenvironment in 
order to create metastatic niches, which are tumour-supporting environments97. 
There are frequent genetic differences between primary tumours and metastases in 
BC from the same patient, suggesting distinct genetic profiles of primary tumours and 
corresponding metastases, the interactions of tumour cells and their 
microenvironment are regulated by different networks of cytokines and growth 
factors, and primary and metastatic brain tumours have been shown to be infiltrated 
by different populations of bone-marrow derived cells, which can be mobilised into 
the circulation and incorporate into tumour microenvironments, modulating them30,98. 
In a study on serous epithelial ovarian cancer, the genetic differences between 
primary tumours and metastases suggest that their major clone is not the same99. 
The differences mentioned above illustrate the relevance of studying the 
microenvironments of both tumours to compare their elements and unravel the 
alteration of tumour behavior from primary tumour to metastasis. The analysis of 
these parameters should elucidate possible crosstalks between elements of both 
tumours’ microenvironments. It would be interesting to know which and how changes 
in the metastasis influenced HR and HER2 statuses. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 BrMets are a serious obstacle in cancer patient care and a significant indicator 
of dismal prognosis41. Although the CNS has been considered to be an immune-
privileged site, increasing evidence supports the role of immune infiltrating cells 
and a strong association with TILs density and improved OS in CNS metastases77. 
This immune microenvironment may be targeted by immune-modulating therapies, 
such as immune checkpoint inhibitors100. Thus, the main objective of this project 
was to investigate the association between components of the immune compartment 
of BrMets (total TILs, and CD4+ TILs and CD8+ TILs) and their clinical relevance. 
Controversial results have been reported in published studies and little is known 
about whether TILs correlate with patient survival in different tumour types101. 
However, in the clinical setting, we obtained promising results that point stromal TILs 
and CD8+ TILs as biomarkers of better prognosis in patients with BrMets. Further 
studies are expected to confirm our findings in a broader cohort.  
 Our secondary objectives were more dependent on the size of the cohort, and 
our purpose to study events like the presence of reactive astrocytes and expression 
of PD-L1 will be pursued upon the expansion of this series of cases. The use of 
TMAs might have also been a limitation since immune infiltration may be 
heterogeneous and this heterogeneity is not captured by TMAs. 
 Furthermore, we also analysed a paired set of primary breast tumours and 
secondary lesions in the brain and found molecular alterations in a significant number 
of cases in our cohort. This stresses that determination of targetable proteins should 
be performed in metastases, independently of the findings in primary tissues, given 
that these patients may benefit from a different treatment strategy. 
 Overall, our results show that the relation between cancer cells and the host is 
constantly changing premises, so it must be mandatory for researchers and clinicians 
to work in close touch to unravel the mechanisms underlying the metastatic process 
in different organs. This could provide therapeutic alternatives in some specific 
windows of opportunity to patients with apparently no more, being the development 
of clinical trials regarding immunotherapies particularly desirable in the context of 
CNS pathologies. 
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7 APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1 | Representative images of H&E tissue sections with 
scores found in this study. Magnification X200. 
Figure A2 | Representative images of tissue sections immunostained for 
CD4 with scores found in this study. Magnification X200. 
Figure A3 | Representative images of tissue sections immunostained for CD8 with scores found in this 
study. Magnification X200. 
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Figure A4 | 12 months-overall survival according to the origin of the primary tumour (top) 
and comparing breast with non-breast metastatic disease (bottom) (n=55). P-value was 
calculated using log-rank (Mantel-Cox) test, and significance was set as p<0.05. 
